TNG:EPA
Transgene SA
€0.73
arrow_upward
+0.27%(+0.0020) 1 天
10月7日, GMT+2 09:48:39 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 TNG 生成关键数据洞见…
开盘价
€0.73
最高价
€0.73
最低价
€0.73
市值
1.95亿
平均成交量
13.73万
成交量
1.09万
52 周最高价
€1.50
52 周最低价
€0.69
每股收益
-€0.17
流通股数
2.79亿
员工人数
160
开盘价
€0.73
最高价
€0.73
最低价
€0.73
市值
1.95亿
平均成交量
13.73万
成交量
1.09万
52 周最高价
€1.50
52 周最低价
€0.69
每股收益
-€0.17
流通股数
2.79亿
员工人数
160
新闻报道
来自网络来源和新闻合作伙伴
www.tmgm.com
·
11分钟前
道琼斯期货下跌，美国国债收益率在FOMC会议纪要公布前反弹
www.tmgm.com
·
1天前
由于市场对美联储加息预期缓和，道琼斯期货上涨
UA.NEWS
·
17小时前
标普500指数和纳斯达克指数收于历史新高—— 阿纳多卢通讯社
OR新媒体
·
7小时前
标普500再创新高，但这场派对几乎只有AI在跳舞
资料
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA简介